MARIFARM LLC PRODUCTION ABOUT US

Size: px
Start display at page:

Download "MARIFARM LLC PRODUCTION ABOUT US"

Transcription

1 MARIFARM LLC PRODUCTION ABOUT US 2018

2 KEY INFORMATION COMPANY NAME: HEADQUARTERS: OWNERSHIP: SHARE CAPITAL: SHARE CAPITAL: FOUNDED: Marifarm LLC Maribor, Slovenia (EU) 100% ARTERIUM International BV ,46 EUR 101 employees as SERVICES: 0 1 The company provides complete or partial production process of semi-solid dosage forms, liquid dosage forms, solid dosage forms, blister packing and quality control service. Most of the revenue comes from production and packaging of medicines for known clients. SLOVENIA

3 COMPETITIVE ADVANTAGES: SPEED FLEXIBILITY COMPETITIVE PRICES LOCATION our processes are carried out faster than competitors we fit to our customers needs we offer attractive price/quality ratio excellent infrastructure connection with EU and countries of Southeast Europe 0 2

4 OUR CERTIFICATES: CERTIFICATE OF EU-GMP IN COMPLIANCE WITH: Manufacturing operations of non-sterile products: Quality control testing: Packaging: Liquids for internal use semi-solid suppositories Tablets Capsules Other: Pessaries Chemical / Physical Primary (capsules, hard shell) Secondary GDP (GOOD DISTRIBUTION PRACTICES) HACCP (HAZARD ANALYSIS AND CRITICAL CONTROL POINTS) 0 3

5 SERVICE PORTFOLIO: SEMI-SOLID DOSAGE FORMS: LIQUID DOSAGE FORMS: BLISTERING: SOLID DOSAGE FORMS: Ointments Syrups Alu/Alu Tablets Creams Gels Drops Suspensions Alu-PVC/PVDC Capsules Effervescent tablets 0 4

6 GMP/GDP INSPECTION BY REGULATOR AUTHORITY (AGENCY) Public Agency of the Republic of Slovenia for Medicinal Products and Medical Devices (JAZMP) The last GMP inspection and verification was in December 2017 (extended licence) The last GDP inspection was in August

7 CERTIFICATE OF GMP COMPLIANCE MANUFACTURING OPERATIONS Non-sterile products (processing operations for the following dosage forms) Tablets Capsules, hard shell Liquids for internal use Semi-solid pharmaceutical dosage forms Suppositories Other: Pessaries Batch certification Packaging Primary packaging Capsules, soft shell Liquids for internal use Semi-solids Suppositories Tablets Other non-sterile medicinal products: Pessaries Secondary packaging Quality control testing Chemical / Physical 06

8 OBJECTIVES AND STRATEGIC POLICIES, QUALITY POLICY to maintain QUALITY of the products in accordance with the highest quality criteria to promote the IN- VENTION of innovative management, creativity and efficiency to REDUCE RISKS in all stages of the production process to commit our users and customers to the long-term PART- NERSHIP promotion of our products and services to provide a high level of professional and business SUCCESS 07

9 FACILITY SIZE PREMISES AREA IN M2 Production area 3.701,73 Warehouse 1.427,93 Office Technical support area Quality control 2.542, ,48 449,24 Total combined area (incl. parking space etc.) ,42 08

10 PRODUCTION CAPACITIES Primary and secondary packaging: Manufacture of semi-solids: 750 million tablets/per year 100 tones/per year Manufacture of liquid oral pharmaceutical forms: Syrups: Herbal extracts: 400 tones/per year 250 tones/per year Manufacture of effervescent Capsulation: Storage capacity: 20 million tablets/per year 240 million capsules/per year 1500 pallet positions 09

11 PRODUCTION CAPABILITIES PRIMARY AND SECONDARY PACKAGING TABLETS AND CAPSULES 2 blister packaging machines Mediseal CP600/P blister packaging machine Mediseal CP200/ Capacity: 80 million blisters per/year Filling line for filling tablets/capsules into 10

12 PRIMARY AND SECONDARY PACKAGING 11

13 PRODUCTION OF SEMI-SOLID DOSAGE FORMS OINTMENTS, CREAMS 12

14 SUPPOSITORIES, PESSARIES 13

15 PRODUCTION OF LIQUID ORAL DOSAGE FORMS SYRUPS, SOLUTIONS 14

16 PRODUCTION OF SOLID ORAL DOSAGE FORMS EFFERVESCENT CAPSULES 15

17 ABOUT US WAREHOUSE CAPACITY OF 1500 PALLETS POSITIONS 16

18 QUALITY ASSURANCE AND QUALITY CONTROL Chemical and physical testing Starting materials Packaging materials Semi-finished products Finished products Stability studies in accordance with ICH guidelines Contract analysis 17

19 INTERNATIONAL COOPERATION Our business partners: 18

20 CONTACT INFORMATION MARIFARM LLC Minaіikova ulica 8, SI-2000 Maribor, Slovenia, European Union Tel.: , Fax: , Director: mag. Romana Fišer, 1 9

21 THANK YOU FOR YOUR ATTENTION 2018

MEDIS International, a.s., Karlovo náměstí 3, Praha 2, tel :

MEDIS International, a.s., Karlovo náměstí 3, Praha 2, tel : MEDIS INTERNATIONAL a.s. 110 00 Praha 1, Olivova 4/2096 MEDIS PHARMA Bolatice Industrial zone Bolatice, region of Opava, Czech Republic MEDIS International a.s. started to build a new facility in October

More information

Bringing ideas to life. Full-service pharmaceutical, nutraceutical and cosmetic contract manufacturing

Bringing ideas to life. Full-service pharmaceutical, nutraceutical and cosmetic contract manufacturing Bringing ideas to life Full-service pharmaceutical, nutraceutical and cosmetic contract manufacturing Bringing ideas to life We built our Swiss pharmaceutical company on one idea born over 70 years ago,

More information

MEDIS INTERNATIONAL a.s Praha 1, Olivova 4/2096 MEDIS PHARMA Bolatice. Industrial zone Bolatice, region of Opava, Czech Republic

MEDIS INTERNATIONAL a.s Praha 1, Olivova 4/2096 MEDIS PHARMA Bolatice. Industrial zone Bolatice, region of Opava, Czech Republic MEDIS INTERNATIONAL a.s. 110 00 Praha 1, Olivova 4/2096 MEDIS PHARMA Bolatice Industrial zone Bolatice, region of Opava, Czech Republic In October 2008 MEDIS International a.s. started the building of

More information

AKRIKHIN: COMPANY PRESENTATION

AKRIKHIN: COMPANY PRESENTATION AKRIKHIN: COMPANY PRESENTATION AKRIKHIN OVERVIEW (1) Akrikhin at a glance Member of Polpharma Group Market position In ТОP 10 largest Russian manufacturers with a turnover more than $200 millions in 2013

More information

Single market, implementation and legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations.

Single market, implementation and legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations. EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, implementation and legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, March 2002

More information

Quality Assessment & GMP Similarities & Differences

Quality Assessment & GMP Similarities & Differences Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences

More information

KSP ID. Chairman. Dr. Abdul Rahman Abdullah Al-Awadi. Date of Establishment. 15 th May Ownership

KSP ID. Chairman. Dr. Abdul Rahman Abdullah Al-Awadi. Date of Establishment. 15 th May Ownership KSP ID Chairman Dr. Abdul Rahman Abdullah Al-Awadi Date of Establishment 15 th May 1994 Ownership A joint venture between National Pharmaceutical Industries Co. & Securities Group Co. Products Manufacturing,

More information

Dynamic Future. Reliable Partnership. Company Profile of the Aenova Group

Dynamic Future. Reliable Partnership. Company Profile of the Aenova Group Dynamic Future. Reliable Partnership. Company Profile of the Aenova Group Dynamic Future. Reliable Partnership. With a turnover of approximately 1 billion USD, the Aenova Group is one of the leading companies

More information

Medicine Variations Guideline

Medicine Variations Guideline Medicine Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 30 th March 2017 Version 2.0 Chief of Pharmaceutical Product Regulation: Dr/Roaya Al Abbasi Date: NHRA CEO Approval:

More information

Medicines Variations Guideline

Medicines Variations Guideline Medicines Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 27/08/2014 Version 1.1 Chief of Pharmaceutical Product Regulation: Dr / Roaya Al Abbasi Date: NHRA CEO Approval:

More information

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September

More information

APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION

APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION Page 1 of 13 May 2008 APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION HUMAN VETERINARY NATIONAL AUTHORISATION IN MRP MRP variation number 1A : / / / / / COMMUNITY AUTHORISATION EMEA variation number

More information

A.1 Contents file 4 to 5 A.1 (1)

A.1 Contents file 4 to 5 A.1 (1) Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW

More information

Actavis Italy. Nerviano Plant

Actavis Italy. Nerviano Plant Actavis Italy Nerviano Plant Starting out in 1901 in Jerusalem The company known today as Teva was established as a small wholesale drug business by Chaim Salomon, Moshe Levin and Yitschak Elstein. (They

More information

Process Systems M+W Process Industries GmbH

Process Systems M+W Process Industries GmbH Process Systems M+W Process Industries GmbH Challenges in the Life Science Industry The manufacture of medicines in solid, semi-solid and liquid forms is a challenge for every pharmaceutical company. This

More information

BLISTER PACKING MACHINES AND SERVICES THAT OFFER FLEXIBILITY AND HIGH QUALITY BLISTER PACKS FROM A WIDE VARIETY OF PACKAGING MATERIALS.

BLISTER PACKING MACHINES AND SERVICES THAT OFFER FLEXIBILITY AND HIGH QUALITY BLISTER PACKS FROM A WIDE VARIETY OF PACKAGING MATERIALS. BLISTER PACKING MACHINES AND SERVICES THAT OFFER FLEXIBILITY AND HIGH QUALITY BLISTER PACKS FROM A WIDE VARIETY OF PACKAGING MATERIALS. 06 1. PACKAGING SOLUTIONS 07 1. PACKAGING SOLUTIONS SMALL SCALE,

More information

Pharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire

Pharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire Pharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire Atieno Ojoo Technical specialist, Pharmaceuticals UNICEF Supply Division 20 th October 2008, UNICEF

More information

A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999

A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline

More information

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU

More information

Page 1

Page 1 Engineers to Healthcare Industry INTERTECH EQUIPTECHNOLOGIES PVT. LTD. Company Presentation 2014 www.intertechequip.com Page 1 INTERTECH Production facility Total Fabrication Area 75,000 ft2 & Clean room

More information

Validation Requirements for Nutrition Products

Validation Requirements for Nutrition Products DC1 Validation Requirements for Nutrition Products Supply Division Dimitris Catsoulacos Quality Assurance Specialist UNICEF Supply Division Nutrition Supplier Meeting 14-16 June 2017, Copenhagen Slide

More information

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines

More information

Good manufacturing practices

Good manufacturing practices The rules governing medicinal products in the European Union Volume 4 Good manufacturing practices Medicinal products for human and veterinary use 1998 Edition EUROPEAN COMMISSION Directorate General III

More information

Complexity of Retention Samples Selection in non-traditional Bioequivalence studies

Complexity of Retention Samples Selection in non-traditional Bioequivalence studies Complexity of Retention Samples Selection in non-traditional Bioequivalence studies Nageshwar R Thudi Ph.D. Director-Clinical R&D Teva Pharmaceuticals Disclaimer The views expressed herein are the views

More information

GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE

GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Finished Pharmaceutical Product Questionnaire This questionnaire is used to collect information from vendors with regards to finished pharmaceutical products

More information

ISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary

ISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE September/October 2008, Vol. 28 No. 5 This executive summary provides an overview of the second edition of the ISPE Baseline Guide:

More information

Microbiological Consideration for Non-Sterile Pharmaceutical

Microbiological Consideration for Non-Sterile Pharmaceutical May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control

More information

Annex Draft Annex

Annex Draft Annex Anmerkung 1: Dieses Vergleichsdokument wurde nach bestem Wissen und Gewissen erstellt und ist rechtlich nicht bindend. Es gelten die von der EMA veröffentlichten Dokumente in der jeweiligen Form. Anmerkung

More information

GUIDELINES FOR SUBMISION OF POST- APPROVAL VARIATION MEDICINE APPLICATIONS

GUIDELINES FOR SUBMISION OF POST- APPROVAL VARIATION MEDICINE APPLICATIONS GUIDELINES FOR SUBMISION OF POST- APPROVAL VARIATION MEDICINE APPLICATIONS FOOD, MEDICINE AND HEALTH CARE ADMINSTRATION AND CONTROL AUTHORITY OF ETHIOPIA (EFMHACA) First Edition December, 2015 Table of

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL EDICINES CONTROL COUNCIL LICENCE APPLICATION TO ANUFACTURE, IPORT OR EXPORT EDICINE An application form for the purpose of obtaining a licence or renewing a licence in terms of the provisions of the edicines

More information

UNICEF Quality Assurance in the procurement of medicines

UNICEF Quality Assurance in the procurement of medicines UNICEF Quality Assurance in the procurement of medicines Peter S. Jakobsen 30 October 2006 Quality Assurance Centre SUPPLY DIVISION Today s presentation addresses 3 questions: How is UNICEF involved in

More information

Chapter 8 Contract Manufacture and Contract Analysis

Chapter 8 Contract Manufacture and Contract Analysis ASEAN Guidelines on GMP for Traditional Medicines Chapter 8 Contract Manufacture and Contract Analysis Prepared by: AATMI/Philippines Approved by: ASEAN TMHS GMP Task Force Endorsed by: ASEAN TMHS Product

More information

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels

More information

Polestar Power Industries (Pharma Division) Pioneer Manufacturer Of Beta-Lactum & Cephalosporin

Polestar Power Industries (Pharma Division) Pioneer Manufacturer Of Beta-Lactum & Cephalosporin Polestar Power Industries (Pharma Division) Pioneer Manufacturer Of Beta-Lactum & Cephalosporin R Polestar Power Industries (Pharma Division) Vill. Damuwala, Haripur Road, Barotiwala, Tehsi l Baddi, Distt.

More information

Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets

Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments

More information

KINGSMANN CARE GROUP

KINGSMANN CARE GROUP PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting

More information

Appendices! Product quality documents. Technical guidelines. (Translation from Original Chinese Version)

Appendices! Product quality documents. Technical guidelines. (Translation from Original Chinese Version) Appendices! (Translation from Original Chinese Version) Product quality documents Technical guidelines Appendix I General tests for various dose forms of pcms The general tests for various dose forms of

More information

Management Team. Over 35 years experience in the pharmaceuticals industry

Management Team. Over 35 years experience in the pharmaceuticals industry 2017 1 Overview Located in Bangalore, a Dedicated cgmp and cglp Compliance Laboratory Established in September 2010 Approved Contract research Organization by India FDA Approved by Health Canada since

More information

Orange and Yellow Guides

Orange and Yellow Guides PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING FIELD? Dr. Alison M.Beaney Regional Quality Assurance Specialist North-East England PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING

More information

JANUARY I. Purpose of this invitation for EoI. II. Background

JANUARY I. Purpose of this invitation for EoI. II. Background First Global Fund and Global Drug facility Invitation to manufacturers of first, second and third-line anti-tuberculosis medicines to submit an Expression of Interest (EoI) for product evaluation by Expert

More information

C360 DEEP DRAW THERMOFORMING MACHINE

C360 DEEP DRAW THERMOFORMING MACHINE C360 DEEP DRAW THERMOFORMING MACHINE C360 DEEP DRAW THERMOFORMING MACHINE C360 The C360 is IMA SAFE s latest trend setting a thermoformer designed for deep draw packaging. This modular designed line has

More information

Comparison of Guidelines of Indian GMP with WHO GMP

Comparison of Guidelines of Indian GMP with WHO GMP Comparison of Guidelines of Indian GMP with WHO GMP By Dr. Uma Vasireddy, M.Pharm,Ph.D.., Professor and Principal, KIPS,Wgl, INDIA 1 Outline of Presentation Introductory Elements Section wise Comparison

More information

TR135 BLISTER PACKAGING MACHINE

TR135 BLISTER PACKAGING MACHINE TR135 BLISTER PACKAGING MACHINE TR135 MADE EASY FOR YOU TR135 is a medium speed blister packaging machine based on a established technology and ease of use, also for semi-skilled operators. With the best

More information

S terile. Injections HANDBOOK OF PHARMACEUTICAL. VOLUME 20 - Part One Drug Development - Sterile Injections GENERIC DEVELOPMENT

S terile. Injections HANDBOOK OF PHARMACEUTICAL. VOLUME 20 - Part One Drug Development - Sterile Injections GENERIC DEVELOPMENT HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT S terile Injections VOLUME 20 - Part One Drug Development - Sterile Injections GENERIC DEVELOPMENT Handbook of Pharmaceutical Generic Development Series Sterile

More information

Current Global GMP Status and Trends With Focus on EU & PIC/S JPMA Annual Meeting, Tokyo & Osaka, September 2012 Dr.-Ing.

Current Global GMP Status and Trends With Focus on EU & PIC/S JPMA Annual Meeting, Tokyo & Osaka, September 2012 Dr.-Ing. Current Global GMP Status and Trends With Focus on EU & PIC/S JPMA Annual Meeting, Tokyo & Osaka, September 2012 Dr.-Ing. Stephan Rönninger Pharma Medicines Technical Operations Global Quality & Compliance,

More information

PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS

PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 010-3 1 October 2008 PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS

More information

WHO GENERAL GUIDANCE ON VARIATIONS TO MULTISOURCE PHARMACEUTICAL PRODUCTS. (February 2014)

WHO GENERAL GUIDANCE ON VARIATIONS TO MULTISOURCE PHARMACEUTICAL PRODUCTS. (February 2014) February 2014 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 World Health Organization 2014 All rights reserved.

More information

Aspen Investor Site Visit Port Elizabeth Facilities. June 2014

Aspen Investor Site Visit Port Elizabeth Facilities. June 2014 Aspen Investor Site Visit Port Elizabeth Facilities June 2014 Aspen Aspen has a proud heritage dating back more than 160 years. The Group provides access to high quality, effective, affordable medicines

More information

ICH Q11 Development & manufacture of drug substances

ICH Q11 Development & manufacture of drug substances ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical

More information

Requirements to the Registration of Medicinal products in the Republic of Armenia

Requirements to the Registration of Medicinal products in the Republic of Armenia Requirements to the Registration of Medicinal products in the Republic of Armenia Yerevan 2017 Requirements to the Registration of Medicinal products in the Republic of Armenia Current requirements to

More information

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA Ministry of Industry and Trade/ Department of pharmaceutical and medical industry development Moscow September 22, 2017 MEDICINES CIRCULATION SYSTEM IN THE RUSSIAN FEDERATION Ministry of Healthcare Medicines

More information

Public Assessment Report. Scientific discussion. Kruidvat Paracetamol liquid caps 500 mg, soft capsules. (paracetamol) NL License RVG:

Public Assessment Report. Scientific discussion. Kruidvat Paracetamol liquid caps 500 mg, soft capsules. (paracetamol) NL License RVG: Public Assessment Report Scientific discussion Kruidvat Paracetamol liquid caps 500 mg, soft capsules (paracetamol) NL License RVG: 116359 Date: 10 April 2017 This module reflects the scientific discussion

More information

Critical Path to TB drug Regimens 2016 Workshop

Critical Path to TB drug Regimens 2016 Workshop Critical Path to TB drug Regimens 2016 Workshop AT A GLANCE Quality Pharmaceutical manufacturing company from Kenya Sales KES 2.26B (USD 22.6M) 2015 Unaudited 65% Business from Donors Portfolio of more

More information

Your partner in the pharmaceutical industry

Your partner in the pharmaceutical industry English Micronisation- and milling service Micronised by GfM Your API Particle size (µm) Your partner in the pharmaceutical industry The... always that little bit finer. We are a family business in the

More information

EU and FDA GMP Regulations: Overview and Comparison

EU and FDA GMP Regulations: Overview and Comparison THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational

More information

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality

More information

TABLETS CAPSULES OINTMENTS SACHETS INJECTABLES DRY SYRUPS

TABLETS CAPSULES OINTMENTS SACHETS INJECTABLES DRY SYRUPS TABLETS CAPSULES OINTMENTS SACHETS INJECTABLES DRY SYRUPS INTRODUCTION We are a dynamic & a optimistic player in the healthcare industry, having vision to create a truly international healthcare company

More information

Pharmaceutical Sciences

Pharmaceutical Sciences SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning

More information

Int. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries

Int. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries Review Article Process Validation of Tablet Dosage Form in Industries Ram Mohan S.R, N. Vishal Gupta* Pharmaceutical Quality Assurance group, Dept of Pharmaceutics, JSS University, Sri ShivarathreeshwaraNagara,

More information

Elemental impurities Expectations for APIs and Excipients in the EU

Elemental impurities Expectations for APIs and Excipients in the EU Elemental impurities Expectations for APIs and Excipients in the EU Implementation strategy in the European Pharmacopoeia Dr. Ulrich Rose Head of Division A European Pharmacopoeia Department EDQM 1 Elemental

More information

Annex 14 WHO guidelines for drafting a site master file 136

Annex 14 WHO guidelines for drafting a site master file 136 World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix

More information

Our manufacturing facility is designed to comply in accordance to the stringent Schedule M GMP Guidelines.

Our manufacturing facility is designed to comply in accordance to the stringent Schedule M GMP Guidelines. Dales Remedies Pvt Ltd was founded in 1994 as a pioneer in the manufacture of wide range of pharmaceutical formulations such as creams, gels, ointments, lotions and mouthwash. Currently we have a separate

More information

QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION

QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/W 1/2011 2 Annexes 22 July 2011 QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PIC/S 2011 Reproduction

More information

Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products.

Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. 3rd FDA/PQRI Conference on Advancing Product Quality March 22-24, 2017 TRACK #2 Achieving Drug Product Quality: Novel

More information

Managing Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA

Managing Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach

More information

PMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft)

PMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft) PMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft) March 30, 2018 Pharmaceuticals and Medical Devices Agency Innovative Manufacturing Technology

More information

PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland

PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec 2004 Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland cca@iol.ie 1 FDA Context 1) FDA 5-Part Strategic Plan Protect &

More information

Quality is Our Promise.

Quality is Our Promise. Quality is Our Promise. Our goal at KRS Global Biotechnology is to provide the highest quality pharmaceutical preparations. We accomplish this with an unrivaled quality assurance and quality control program

More information

Performance Testing of Novel Dosage Forms

Performance Testing of Novel Dosage Forms RQA Ireland Regional Forum - Athlone, May 2016 Quality Considerations Pharma and Biopharma Performance Testing of Novel Dosage Forms Terry Way BPharm MAPS Dissolution Science Consultant Glasside Technologies

More information

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION 1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS

More information

TR200 BLISTER PACKAGING MACHINES

TR200 BLISTER PACKAGING MACHINES TR200 BLISTER PACKAGING MACHINES TR200 TR200 is an extremely versatile, medium production speed blister packaging machine that was designed for production cycles that require frequent size changeovers.

More information

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008 Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...

More information

Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education

Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education Loyd V. Allen, Jr., Ph.D. Professor & Chair Emeritus University of Oklahoma HSC College of Pharmacy Editor-in in-chief International

More information

A STUDY ON VARIATIONS IN PHARMACEUTICAL PRODUCTS IN PHILIPPINES AND VARITAION POLICIES IN US, CANADA, AUSTRALIA

A STUDY ON VARIATIONS IN PHARMACEUTICAL PRODUCTS IN PHILIPPINES AND VARITAION POLICIES IN US, CANADA, AUSTRALIA ISSN: 2230-7346 Jignesh Shah et al. / JGTPS / 6(1)-(2015) 2340 2344 (Review Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com A STUDY ON VARIATIONS IN PHARMACEUTICAL

More information

International Journal of Generic Drugs

International Journal of Generic Drugs Photostability STABILITY TESTING in New Drug Products evaluating photostability is foremost for new chemical entities only - not in generic drugs, provided the container-closure protection is the same

More information

Qualified Persons in the Pharmaceutical Industry Study Guide

Qualified Persons in the Pharmaceutical Industry Study Guide Qualified Persons in the Pharmaceutical Industry Study Guide Guide to the knowledge and practical experience required by Qualified Persons relating to pharmaceutical manufacturing in the UK February 2013

More information

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.

More information

Public Assessment Report Scientific discussion. Celecoxib Pfizer (celecoxib) SE/H/1076/01-02/DC

Public Assessment Report Scientific discussion. Celecoxib Pfizer (celecoxib) SE/H/1076/01-02/DC Public Assessment Report Scientific discussion Celecoxib Pfizer (celecoxib) SE/H/1076/01-02/DC This module reflects the scientific discussion for the approval of Celecoxib Pfizer. The procedure was finalised

More information

to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government No. 29.

to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government No. 29. STATUTORY INSTRUMENTS SUPPLEMENT No. 8 28th March, 2014 STATUTORY INSTRUMENTS SUPPLEMENT to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government.

More information

Inspection. Implementation of ICH Q8, Q9, Q10

Inspection. Implementation of ICH Q8, Q9, Q10 Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory

More information

HISTORY AND MILESTONES

HISTORY AND MILESTONES HISTORY AND MILESTONES HISTORY AND MILESTONES DOC S.r.l., Documentation Organization & Consultancy, was established in 1997 by MASCO group C.E.O. Eng. Alberto Borella and Eng. Paolo Curtò who became Managing

More information

VALIDATION STRATEGIES FOR MULTI-PRODUCT FACILITIES

VALIDATION STRATEGIES FOR MULTI-PRODUCT FACILITIES VALIDATION STRATEGIES FOR MULTI-PRODUCT FACILITIES By: Justin Roose Head Validation Engineer Product Quality Assurance (Global Compliance) 1 Session Agenda 1. Instruction 2. Questions 3. Do it! Open-forum

More information

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles

More information

The European Approach on Large Sample Sizes in the context of a PAT Environment

The European Approach on Large Sample Sizes in the context of a PAT Environment The European Approach on Large Sample Sizes in the context of a PAT Environment Dr. Michael Wierer, Deputy Head, European Pharmacopoeia Department, European Directorate for the Quality of Medicines & HealthCare

More information

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 14 December 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4

More information

WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND

WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer

More information

Barcodes on Unit of Use

Barcodes on Unit of Use Barcodes on Unit of Use 1 What hospitals need Hospitals need medications Ready-to-Administer In Unit-of-Use With Barcode 2 What hospitals need Ready-to-Administer If not, must go through additional pharmacy

More information

IMP Management and Accountability

IMP Management and Accountability This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document

More information

Technical updates medicines inspections: Finished Pharmaceutical Products (FPP)

Technical updates medicines inspections: Finished Pharmaceutical Products (FPP) Technical updates medicines inspections: Finished Pharmaceutical Products (FPP) Vimal Sachdeva, Technical Officer (Inspector) WHO Prequalification Team (PQT), WHO/HIS/EMP/RHT 20 Avenue Appia, CH - 1211,

More information

STABILITY TESTING OF NEW DRUG

STABILITY TESTING OF NEW DRUG VICH GL5 (STABILITY 3) May 1999 For implementation at Step 7 STABILITY TESTING ESTING: PHOTOSTABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS Recommended for Implementation at

More information

Guidance Document 01 January 2016 CONTENTS. 1. Introduction Background 1.2. Objectives 1.3. Scope and application 1.4 APIMF holder obligations

Guidance Document 01 January 2016 CONTENTS. 1. Introduction Background 1.2. Objectives 1.3. Scope and application 1.4 APIMF holder obligations GUIDANCE ON AMENDMENTS TO AN ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) SUBMITTED IN SUPPORT OF A PREQUALIFIED PHARMACEUTICAL PRODUCT (FPP) OR PREQUALIFIED ACTIVE PHARMACEUTICAL INGREDIENT (API)

More information

Guide for Recall of Medicinal Products for Human and Veterinary Use

Guide for Recall of Medicinal Products for Human and Veterinary Use Guide for Recall of Medicinal Products for Human and Veterinary Use SUR-G0019-3 22 NOVEMBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes

More information

Introduction to CMC Regulatory Affairs

Introduction to CMC Regulatory Affairs Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4

More information

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 11 Status : APPROVED Effective: 09/07/2017 Page 2 of 32 Quality Manual Table of Contents

More information

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Date: April 23, 2012 Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Key Messages Importation quality control testing for pharmaceutical, biological/biotechnology

More information

Formulation Development

Formulation Development Quality by Design and Formulation Development WF Busch Senior Application Development Specialist Dow Chemical Company IPEC Americas, Quality by Design Committee 5 May 2010 Disclaimer The views and opinions

More information

O RAL C. apsules HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT. VOLUME II - PART ONE Drug Development - Solid Oral Dosage Forms.

O RAL C. apsules HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT. VOLUME II - PART ONE Drug Development - Solid Oral Dosage Forms. HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT O RAL C Immediate Release apsules VOLUME II - PART ONE Drug Development - Solid Oral Dosage Forms Handbook of Pharmaceutical Generic Development Series ORAL

More information

12/10/2011. Development of sterile medicinal products in Dutch hospital pharmacy SEHP Santiago de Compostella. Introduction.

12/10/2011. Development of sterile medicinal products in Dutch hospital pharmacy SEHP Santiago de Compostella. Introduction. Development of sterile medicinal products in Dutch hospital pharmacy SEHP 2011 Santiago de Compostella Introduction Willem Meulenhoff (1971) Production Pharmacist at NV Organon (MSD) Head of the Production

More information

HIV/AIDS Programme USER GUIDE DRUG REGULATORY STATUS DATABASE (DRS) Version 2

HIV/AIDS Programme USER GUIDE DRUG REGULATORY STATUS DATABASE (DRS) Version 2 HIV/AIDS Programme USER GUIDE DRUG REGULATORY STATUS DATABASE (DRS) Version 2 November 2012 HIV/AIDS Programme USER GUIDE DRUG REGULATORY STATUS DATABASE (DRS) Version 2 November 2012 WHO Library Cataloguing-in-Publication

More information

STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS

STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW

More information